US FDA approves Asahi Kasei drug for persistent herpes sores
FDA approved Asahi Kasei’s drug for persistent herpes simplex virus sores in certain patients with weakened immune systems who did not respond to available antiviral treatments.
FDA approved Asahi Kasei’s drug for persistent herpes simplex virus sores in certain patients with weakened immune systems who did not respond to available antiviral treatments.